FDA: pharmaceutical giant Roche competing products or fatal blood glucose meters – Roche – Pharmaceutical Industry A recent news that the product of global pharmaceutical giant Roche is the destruction of their blood glucose meters can be fatal.
In a U.S. FDA site on August 13 last year, FDA issued a warning that diabetics should avoid using the diagnosis of GHD-PQQ on the alert, the FDA said in August 1977 to 2009 they collect at least 13 cases, six cases occurred in 2008 and 2009.
What the Sino-Japanese Friendship Society Hospital, Guang-Wei, director of endocrine and metabolic diseases of the “Daily Economic News” said GHD-PQQ in the diagnosis of the presence of a defect with some not sugars such as glucose, maltose, respond cause false readings high blood glucose meters. If the patient after the pseudo-high-value treatment, insulin injections can cause low blood sugar such as sweating, palpitations and other symptoms, can cause severe coma, age, or even occur in patients with large cerebral infarction and myocardial infarction by death.
Guang-Wei said that the external incident draws attention to death in China, there are manufacturers and therefore abortion maltose infusion program. Knowledge in medicine, so measurements at the hospital, doctor and nurses will be noted that, but now many people buy their own meters, but the Chinese do not eat more than maltose, having a big problem eating.
1 diabetes at the Institute of Chinese medical association showed that people with diabetes in 2009 in China reached 92 million in the first place in the world and thus large consumer market, foreign pharmaceutical giants also entered China, and benefit from diabetes in the China market. The data show that blood glucose monitoring market in the U.S. Johnson & Johnson, Roche of Switzerland and China Yicheng Sheng District is currently in the top three, as Johnson & Johnson and Roche together represent half the market.
means that more than 20 million diabetics test data measured in meters Roche. Roche “Public Relations Manager Xu Chao said in an interview using intravenous infusion of immunoglobulin treatment of diabetes, only 1% of the total number of diabetes patients. But the transition to digital is still vast.
Xu Chao said that Roche knew that you can take immediate measures to assist hospitals in developing countries, standard operating procedures were discovered blood repeatedly held medical care.
It is clear that only doctors know that it is not enough. Reporters called blood products to manage glucose Rocand hotline for customer service, or busy or no one answered, Institute explanation for professional diagnosis, blood glucose meters and sell only hospitals, but also sold to private so that they are employed.
Li Zhebin lawyer told journalists that China recall system is not perfect, he suggested that consumers may be starting point for foreign evidence , appeal to the AQSIQ. To have caused health problems, you can direct to the courts.
